- Advertise
- About OncLive
- Editorial Board
- CureToday.com
- TargetedOnc.com
- CancerNetwork.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
Latest Oncology News
TAS-102 Plus Bevacizumab Misses PFS End Point in Frontline Unresectable Metastatic CRC
October 22nd 2021
Kristi Rosa
The frontline combination of trifluridine/tipiracil and bevacizumab was not found to result in a significant improvement in progression-free survival over capecitabine and bevacizumab in patients with unresectable metastatic colorectal cancer who are not eligible to receive intensive therapy, missing the primary end point of the phase 3 SOLSTICE trial.
Pembrolizumab/Chemo Approved in Europe for Select Locally Recurrent Unresectable or Metastatic TNBC
October 22nd 2021
Kristi Rosa
The European Commission has approved pembrolizumab plus chemotherapy for the frontline treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumors have a PD-L1 expression combined positive score of 10 or higher and who have not previously received chemotherapy for metastatic disease.
FDA Approves Companion Diagnostic for Adjuvant Atezolizumab in Stage II to IIIA NSCLC
October 22nd 2021
Kristi Rosa
The FDA has approved the VENTANA PD-L1 assay to assist in identifying which adult patients with stage II to IIIA non–small cell lung cancer whose tumors have PD-L1 expression on 1% or more of tumor cells are eligible to receive adjuvant atezolizumab following surgery and platinum-based chemotherapy.
Tissue Mapping Center for Cellular Senescence Launched at Yale Cancer Center to Study Human Lymphoid Organs
October 22nd 2021
The National Institutes of Health has awarded a grant to fund cellular senescence research in lymphoid organs at Yale Cancer Center.
Will Slow and Steady Progress in Treating SCLC Win the Race?
October 22nd 2021
Christina T. Loguidice
Clinical advances in treatment of small cell lung cancer have lagged behind those of other tumor types, but the delay is not for lack of effort.
%20copy.jpg?fit=crop&auto=format)
%20copy.jpg?fit=crop&auto=format)
